For example, injecting patient-derived CTCs into solid tissue (e.g., the flanks of mice) could provide a survival advantage by eliminating the need to a) survive in circulation, b) extravasate as an individual cell, and c) survive and outgrow from an individual cell in the absence of potentially stimulating factors from other tumor cells..